VLE Therapeutics
Mark Barrett is the Group CEO & Co-Founder at APC Ltd and VLE Therapeutics. He also serves as an Adjunct Professor at University College Dublin. With a background in Chemical Engineering and a PhD in Optimization and Scale-Up, Mark has extensive experience in research and development within the pharmaceutical industry. His current focus is on accelerating medicines development and reimagining CGT and vaccine manufacture through breakthroughs in manufacturing science and digitization. Mark has also worked at Solid State Pharmaceutical Cluster Ireland, Schering-Plough, and has experience as a Research Intern at FSA/NASA.
This person is not in any offices
VLE Therapeutics
Vaccines, CGTs, and other advanced therapeutics are taking too long to reach patients. Scientists want to move faster, but external manufacturers prioritize ‘contracts’ over the need for innovation and speed in GMP manufacturing. The promise of patient-focused partnerships remains out of reach until now. *Speed through Science* VLE is led by the brightest scientific minds and powered by iACHIEVE© and BioACHIEVE© our digital and process science platforms. For every medicine, we redefine CMC, tech transfer, and GMP operations through digitization and scientific excellence creating a new frontier for medicine acceleration and a new state-of-the-art for GMP manufacturing. *Patient-Focused Partnerships* We constantly strive to understand the unique clinical and CMC landscape of every medicine we work on, enabling us to deliver the manufacturing breakthroughs our partners need to achieve audacious supply chain goals that truly serve patients. *Digital First GMP* Our expertise in manufacturing science and GMP operations is accentuated by our first-in-class digital strategy – iACHIEVE©. By digitizing our process, analytical and manufacturing science breakthroughs we can deliver medicines with the speed that patients deserve and the precision regulators demand.